{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T19:17:18Z","timestamp":1697397438366},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00280-007-0507-7","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T07:06:51Z","timestamp":1180940811000},"page":"713-716","source":"Crossref","is-referenced-by-count":4,"title":["PDGFRalpha\/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment"],"prefix":"10.1007","volume":"61","author":[{"given":"Ernesto","family":"Vigna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Bisconte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Armentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,5]]},"reference":[{"key":"507_CR1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2003.04195.x","volume":"121","author":"F Brito-Babapulle","year":"2003","unstructured":"Brito-Babapulle F (2003) The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 121:203\u2013223","journal-title":"Br J Haematol"},{"key":"507_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","volume":"54","author":"MJ Chusid","year":"1975","unstructured":"Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1\u201327","journal-title":"Medicine (Baltimore)"},{"key":"507_CR3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201\u20131214","journal-title":"N Engl J Med"},{"key":"507_CR4","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","volume":"100","author":"JH Griffin","year":"2003","unstructured":"Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 100:7830\u20137835","journal-title":"Proc Natl Acad Sci USA"},{"key":"507_CR5","first-page":"596","volume":"90","author":"R La Starza","year":"2005","unstructured":"La Starza R, Specchia G, Cuneo A et al (2005) The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 90:596\u2013601","journal-title":"Haematologica"},{"key":"507_CR6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","volume":"19","author":"C Roche-Lestienne","year":"2005","unstructured":"Roche-Lestienne C, Lepers S, Soenen-Cornu V et al (2005) Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19:792\u2013798","journal-title":"Leukemia"},{"key":"507_CR7","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Brockman SR, Paternoster SF et al (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104:3038\u20133045","journal-title":"Blood"},{"key":"507_CR8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","volume":"18","author":"P Vandenberghe","year":"2004","unstructured":"Vandenberghe P, Wlodarska I, Michaux L et al (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18:734\u2013742","journal-title":"Leukemia"},{"key":"507_CR9","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","volume":"101","author":"AD Klion","year":"2003","unstructured":"Klion AD, Noel P, Akin C et al (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660\u20134666","journal-title":"Blood"},{"key":"507_CR10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Robyn J, Akin C et al (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473\u2013478","journal-title":"Blood"},{"key":"507_CR11","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","volume":"101","author":"J Cortes","year":"2003","unstructured":"Cortes J, Ault P, Koller C et al (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714\u20134716","journal-title":"Blood"},{"key":"507_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","volume":"26","author":"P Ault","year":"2002","unstructured":"Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:881\u2013884","journal-title":"Leuk Res"},{"key":"507_CR13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","volume":"359","author":"GJ Gleich","year":"2002","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577\u20131578","journal-title":"Lancet"},{"issue":"8","key":"507_CR14","first-page":"ECR25","volume":"89","author":"M Malagola","year":"2004","unstructured":"Malagola M, Martinelli G, Rondoni M, Ottavini E, Piccaluga PP, Ricci P, Visani G Baccarani M (2004) Soft tissue and skeletal involvement in FIP1L1-PDGFR-\u03b1 positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. Haematological 89(8):ECR25","journal-title":"Haematological"},{"key":"507_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00277-004-0845-z","volume":"83","author":"N Frickhofen","year":"2004","unstructured":"Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H et al (2004) Complete molecular remission af CEL complicated by CNS disease after targeted therapy with imatinib. Annal Hematol 83:477\u2013480","journal-title":"Annal Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0507-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0507-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:46Z","timestamp":1559038006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0507-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0507-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,5]]}}}